Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Cash (2020 - 2025)

Journey Medical (DERM) has disclosed Change in Cash for 6 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 420.81% year-over-year to $4.7 million, compared with a TTM value of $2.5 million through Sep 2025, up 208.7%, and an annual FY2024 reading of -$7.1 million, down 56.31% over the prior year.
  • Change in Cash was $4.7 million for Q3 2025 at Journey Medical, up from -$777000.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $27.4 million in Q4 2021 and bottomed at -$9.1 million in Q2 2023.
  • Average Change in Cash over 5 years is $879052.6, with a median of -$1.5 million recorded in 2024.
  • The sharpest move saw Change in Cash soared 527.25% in 2021, then plummeted 435.86% in 2025.
  • Year by year, Change in Cash stood at $27.4 million in 2021, then tumbled by 110.54% to -$2.9 million in 2022, then soared by 193.14% to $2.7 million in 2023, then plummeted by 180.15% to -$2.2 million in 2024, then soared by 315.91% to $4.7 million in 2025.
  • Business Quant data shows Change in Cash for DERM at $4.7 million in Q3 2025, -$777000.0 in Q2 2025, and $765000.0 in Q1 2025.